These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36810103)

  • 1. Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany.
    Leibrock B; Landfeldt E; Hussong J; Huelle T; Mattheus H; Thiele S; Walter MC; Zemlin M; Moehler E; Dillman U; Abner S; Flotats-Bastardas M
    Orphanet J Rare Dis; 2023 Feb; 18(1):32. PubMed ID: 36810103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
    Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
    Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life of adults with spinal muscular atrophy: insights from a nationwide patient registry in Germany.
    Landfeldt E; Leibrock B; Hussong J; Thiele S; Walter MC; Moehler E; Zemlin M; Dillmann U; Flotats-Bastardas M
    Qual Life Res; 2024 Jul; 33(7):1949-1959. PubMed ID: 38753126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy.
    Lusakowska A; Jedrzejowska M; Kaminska A; Janiszewska K; Grochowski P; Zimowski J; Sierdzinski J; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2021 Mar; 16(1):150. PubMed ID: 33761963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
    Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
    JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-Reported Health-Related Quality of Life of Children with Spinal Muscular Atrophy: Preliminary Insights from a Nationwide Patient Registry in Germany.
    Landfeldt E; Leibrock B; Hussong J; Thiele S; Abner S; Walter MC; Moehler E; Zemlin M; Dillmann U; Flotats-Bastardas M
    J Neuromuscul Dis; 2024; 11(1):117-128. PubMed ID: 38108360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol.
    Ros LAA; Goedee HS; Franssen H; Asselman FL; Bartels B; Cuppen I; van Eijk RPA; Sleutjes BTHM; van der Pol WL; Wadman RI
    BMC Neurol; 2023 Apr; 23(1):164. PubMed ID: 37095427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RegistrAME: the Spanish self-reported patient registry of spinal muscular atrophy.
    Cattinari MG; de Lemus M; Tizzano E
    Orphanet J Rare Dis; 2024 Feb; 19(1):76. PubMed ID: 38373977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RESTORE: A Prospective Multinational Registry of Patients with Genetically Confirmed Spinal Muscular Atrophy - Rationale and Study Design.
    Finkel RS; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Shieh PB; Tizzano E; Desguerre I; Quijano-Roy S; Saito K; Droege M; Dabbous O; Khan F; Renault L; Anderson FA; Servais L
    J Neuromuscul Dis; 2020; 7(2):145-152. PubMed ID: 32039859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy.
    Pechmann A; König K; Bernert G; Schachtrup K; Schara U; Schorling D; Schwersenz I; Stein S; Tassoni A; Vogt S; Walter MC; Lochmüller H; Kirschner J
    Orphanet J Rare Dis; 2019 Jan; 14(1):18. PubMed ID: 30665421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth patterns in children with spinal muscular atrophy.
    De Amicis R; Baranello G; Foppiani A; Leone A; Battezzati A; Bedogni G; Ravella S; Giaquinto E; Mastella C; Agosto C; Bertini E; D'Amico A; Pedemonte M; Bruno C; Wells JC; Fewtrell M; Bertoli S
    Orphanet J Rare Dis; 2021 Sep; 16(1):375. PubMed ID: 34481516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.